| Literature DB >> 25114544 |
Rajakumar Nagarajan1, Daniel Ja Margolis1, Steven S Raman1, David Ouellette1, Manoj K Sarma1, Robert E Reiter2, M Albert Thomas1.
Abstract
Magnetic resonance spectroscopic imaging (MRSI) detects alterations in major prostate metabolites, such as citrate (Cit), creatine (Cr), and choline (Ch). We evaluated the sensitivity and accuracy of three-dimensional MRSI of prostate using an endorectal compared to an external phased array "receive" coil on a 3T MRI scanner. Eighteen patients with prostate cancer (PCa) who underwent endorectal MR imaging and proton (1H) MRSI were included in this study. Immediately after the endorectal MRSI scan, the PCa patients were scanned with the external phased array coil. The endorectal coil-detected metabolite ratio [(Ch+Cr)/Cit] was significantly higher in cancer locations (1.667 ± 0.663) compared to non-cancer locations (0.978 ± 0.420) (P < 0.001). Similarly, for the external phased array, the ratio was significantly higher in cancer locations (1.070 ± 0.525) compared to non-cancer locations (0.521 ± 0.310) (P < 0.001). The sensitivity and accuracy of cancer detection were 81% and 78% using the endorectal 'receive' coil, and 69% and 75%, respectively using the external phased array 'receive' coil.Entities:
Keywords: MRSI; choline; citrate; creatine; external coil; metabolites; prostate cancer; sensitivity
Year: 2013 PMID: 25114544 PMCID: PMC4089813 DOI: 10.4137/MRI.S10861
Source DB: PubMed Journal: Magn Reson Insights ISSN: 1178-623X
Figure 1Comparison of metabolite ratios [(Ch+Cr)/Cit] in 18 PCa patients scanned with the endorectal and external body array ‘receive’ coils.
Note: Significant (P < 0.05) elevation of Ch/Cr observed in cancer locations compared to non-cancer locations in both coils.
Figure 2Comparison of (A) endorectal and (B) external body array MR Spectroscopic Imaging of a 67-year old PCa patient.
Note: Extracted single voxel spectra show a significant (P < 0.05) elevation of Ch/Cr and declined Cit in the right side peripheral zone of the PCa patient in both coils.
FWHM of water and metabolite resonances using endorectal and external body array “receive” coils.
| Peak | Endorectal FWHM Mean ± SD | CV (%) | External body array FWHM Mean ± SD | CV (%) |
|---|---|---|---|---|
| Cancer Cit | 11.73 ± 2.75 | 23.41 | 15.45 ± 6.17 | 39.96 |
| Cancer (Cr+Ch) | 17.71 ± 6.78 | 27.57 | 25.75 ± 8.47 | 32.88 |
| Non-cancer Cit | 11.53 ± 1.73 | 15.02 | 18.83 ± 10.16 | 53.94 |
| Non-cancer (Cr+Ch) | 19.59 ± 6.83 | 27.77 | 28.06 ± 10.80 | 38.49 |
| Water | 25.00 ± 5.16 | 20.64 | 31.00 ± 9.62 | 31.05 |
Note: The FWHM of the water resonance represents global line width whereas the FWHM values of metabolites were derived from spectra extracted from selected locations.
Figure 3Correlation between the maximum ratios [(Ch+Cr)/Cit] of cancer identified in the peripheral zone with external phased array coil vs. endorectal coil MRS.
Note: A positive correlation was observed.
Figure 4ROC curves of MRSI ratios of prostate cancer patients (A) with the endorectal and (B) the external phased array ‘receive’ coils.
Measures of sensitivity, specificity, PPV, NPV, and accuracy of endorectal and external body coil MRSI ratios in discrimination of cancer from non-cancer with ROC curve analysis.
| Parameter | Endorectal coil | External phased array |
|---|---|---|
| CV | 1.35 | 0.77 |
| Sensitivity, % | 81.3 | 68.8 |
| Specificity, % | 75.0 | 81.3 |
| PPV% | 76.5 | 78.6 |
| NPV% | 80.0 | 72.2 |
| AUC, % | 86.9 | 85.9 |
| Accuracy, % | 78.1 | 75.0 |
Abbreviations: CV, cutoff value; PPV, positive predictive value; NPV, negative predictive value; AUC, area under the curve.